AU2006230219A1 - Method for cancer prognosis using cellular folate vitamin receptor quantification - Google Patents

Method for cancer prognosis using cellular folate vitamin receptor quantification Download PDF

Info

Publication number
AU2006230219A1
AU2006230219A1 AU2006230219A AU2006230219A AU2006230219A1 AU 2006230219 A1 AU2006230219 A1 AU 2006230219A1 AU 2006230219 A AU2006230219 A AU 2006230219A AU 2006230219 A AU2006230219 A AU 2006230219A AU 2006230219 A1 AU2006230219 A1 AU 2006230219A1
Authority
AU
Australia
Prior art keywords
cancer cells
cancer
cells
antibody
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006230219A
Other languages
English (en)
Inventor
Phil Ronald Ellis
Lynn C. Hartmann
Christopher Paul Leamon
Philip Stewart Low
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Endocyte Inc
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Purdue Research Foundation
Endocyte Inc
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Purdue Research Foundation, Endocyte Inc, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of AU2006230219A1 publication Critical patent/AU2006230219A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2006230219A 2005-03-30 2006-03-30 Method for cancer prognosis using cellular folate vitamin receptor quantification Abandoned AU2006230219A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66643005P 2005-03-30 2005-03-30
US60/666,430 2005-03-30
PCT/US2006/011376 WO2006105141A1 (en) 2005-03-30 2006-03-30 Method for cancer prognosis using cellular folate vitamin receptor quantification

Publications (1)

Publication Number Publication Date
AU2006230219A1 true AU2006230219A1 (en) 2006-10-05

Family

ID=36754569

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006230219A Abandoned AU2006230219A1 (en) 2005-03-30 2006-03-30 Method for cancer prognosis using cellular folate vitamin receptor quantification

Country Status (10)

Country Link
US (1) US20090081710A1 (https=)
EP (2) EP2199796A1 (https=)
JP (1) JP2008537778A (https=)
CN (1) CN101203759A (https=)
AT (1) ATE460668T1 (https=)
AU (1) AU2006230219A1 (https=)
CA (1) CA2602585A1 (https=)
DE (1) DE602006012816D1 (https=)
RU (1) RU2007139912A (https=)
WO (1) WO2006105141A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
CA2484640C (en) 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
CN101175757B (zh) 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
CA2607444C (en) 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
BRPI0615354A2 (pt) 2005-08-19 2011-05-17 Endocyte, Inc. conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
AU2008224988A1 (en) 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
BR112012002064A2 (pt) * 2009-07-31 2017-05-09 Endocyte Inc método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele
TWI622402B (zh) 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
MX343607B (es) * 2010-11-05 2016-11-11 Morphotek Inc Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.
KR20130140032A (ko) * 2010-11-12 2013-12-23 엔도사이트, 인코포레이티드 암을 치료하는 방법들
BR112013025415B1 (pt) * 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
CN102861020A (zh) * 2012-09-25 2013-01-09 上海交通大学医学院附属仁济医院 叶酸在制备预防大肠腺瘤初发药物中的应用
BR112015008365A2 (pt) 2012-10-16 2017-07-04 Endocyte Inc composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
CN113150145B (zh) 2013-08-30 2025-02-14 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
PL3055332T3 (pl) * 2013-10-08 2020-02-28 Immunogen, Inc. Schematy dawkowania immunokoniugatu anty-FOLR1
WO2015077303A1 (en) 2013-11-19 2015-05-28 Purdue Research Foundation Patient selection method for inflammation
JP6246030B2 (ja) * 2014-03-12 2017-12-13 東芝メディカルシステムズ株式会社 病理染色装置及び病理染色方法
CN116440279B (zh) 2015-09-17 2026-02-24 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
US11313868B2 (en) * 2016-06-14 2022-04-26 Board Of Regents, The University Of Texas System Methods of detecting anti-folic acid antibodies and uses thereof
CN106483282B (zh) * 2016-09-29 2018-08-31 北京世纪沃德生物科技有限公司 一种抗原稳定剂及其制备方法与应用
EP3544999A1 (en) 2016-11-23 2019-10-02 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CN116615455A (zh) * 2020-09-12 2023-08-18 免疫医疗有限公司 用于抗b7h4抗体-药物缀合物疗法的评分方法
CN117741149A (zh) * 2024-02-19 2024-03-22 卡秋(江苏)生物科技有限公司 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989838A (en) 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5846739A (en) * 1995-12-05 1998-12-08 Wisconsin Alumni Research Foundation Immunohistochemical detection assay for carcinoma proliferative status
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
CN1441676B (zh) * 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
EP2168598A1 (en) * 2001-09-28 2010-03-31 Purdue Research Foundation Method of Treatment Using Ligand-Immunogen Conjugates
WO2003089593A2 (en) * 2002-04-19 2003-10-30 Endocyte, Inc. Adjuvant enhanced immunotherapy
CA2484640C (en) 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates

Also Published As

Publication number Publication date
EP2199796A1 (en) 2010-06-23
EP1864133A1 (en) 2007-12-12
RU2007139912A (ru) 2009-05-10
EP1864133B1 (en) 2010-03-10
WO2006105141A1 (en) 2006-10-05
ATE460668T1 (de) 2010-03-15
US20090081710A1 (en) 2009-03-26
CN101203759A (zh) 2008-06-18
CA2602585A1 (en) 2006-10-05
JP2008537778A (ja) 2008-09-25
DE602006012816D1 (de) 2010-04-22

Similar Documents

Publication Publication Date Title
EP1864133B1 (en) Method for breastcancer prognosis using cellular folate vitamin receptor quantification
US8470542B2 (en) Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
Khan et al. Early diagnostic value of survivin and its alternative splice variants in breast cancer
Lara Jr et al. HER‐2/neu is overexpressed infrequently in patients with prostate carcinoma: Results from the California Cancer Consortium screening trial
JP2012177706A (ja) 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
EP3283886B1 (en) Methods for treating lung cancer
Pothos et al. Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma
US9297812B2 (en) Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E
EP1470239B1 (en) Psoriasin expression by breast epithelial cells
US20100303809A1 (en) Methods for the detection and quantitation of pten
Anunobi et al. Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms
EP2707720B1 (en) Diagnosis and prognosis of triple negative breast and ovarian cancer
US20080227098A1 (en) Method for diagnosing cancer of the prostate
US20140030254A1 (en) Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease
US20140148353A1 (en) Protein expression-based classifier for prediction of recurrence in adenocarcinoma
KR20240161980A (ko) 갑상선암의 진단을 위한 신규한 바이오 마커
CN110546510A (zh) 预后方法和在所述方法中有用的试剂盒
EP3271725A1 (en) Materials and methods for detecting androgen receptor splice variants and uses thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application